VT-1598 is under clinical development by Mycovia Pharmaceuticals and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect VT-1598’s likelihood of approval (LoA) and phase transition for Coccidioidomycosis took place on 04 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their VT-1598 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
VT-1598 is under development for the treatment of invasive fungal infections such as coccidioidomycosis or valley fever and cryptococcal meningitis and infections against species such as Cryptococcus, Aspergillus, Rhizopus, and Candida. The drug candidate is administered through oral in the form of tablet and intravenous route. It is second-generation small molecule and targets lanosterol demethylase (CYP51). It is based on Metallophile technology platform.
Mycovia Pharmaceuticals overview
Mycovia Pharmaceuticals(Mycoyia Pharmaceuticals) formerly known as Viamet Pharmaceuticals, is a subsidiary of Viamet Pharmaceuticals Holdings LLC, discovers and develops novel medicinal drugs based on metalloenzyme chemistry and biology technology platform. Its product portfolio includes clinical-stage compounds such as VT-1161, an oral inhibitor used for the treatment of onychomycosis and recurrent vulvovaginal candidiasis; VT-1129, an oral agent for the treatment of cryptococcal meningitis; VT-1598, an oral inhibitor to treat invasive fungal infections, including coccidioidomycosis. The company’s proprietary MIDAS technology (Metalloenzyme Inhibitor Design and Synthesis) enables to discover metalloenzyme inhibitors that target fungal CYP51 of both chronic and life threatening fungal infections. Mycoyia Pharmaceuticals is headquartered in Durham, North Carolina, the US.
Quick View VT-1598 LOA Data
|Highest Development Stage|